Accéder au contenu
Merck

Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

Bioorganic & medicinal chemistry letters (2007-05-26)
Naohisa Ogo, Shinya Oishi, Kenji Matsuno, Jun-ichi Sawada, Nobutaka Fujii, Akira Asai
RÉSUMÉ

Inhibition of Eg5 represents a novel approach for the treatment of cancer. Here, we report the synthesis and structure-activity relationship of S-trityl-L-cysteine (STLC) derivatives as Eg5 inhibitors. Some of these derivatives such as 4f demonstrated enhanced inhibitory activity against Eg5 and induced mitotic arrest with characteristic monoastral spindles in HeLa cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
L-cystéine, 97%
Sigma-Aldrich
L-cystéine, from non-animal source, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
L-cystéine, BioUltra, ≥98.5% (RT)
SAFC
L-cystéine
Sigma-Aldrich
L-cystéine, ≥97%, FG
Sigma-Aldrich
S-Methyl-L-cysteine, substrate for methionine sulfoxide reductase A
Sigma-Aldrich
Fmoc-Cys(Trt)-OH, ≥95.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
S-Carboxymethyl-L-cysteine
Sigma-Aldrich
Boc-Cys(Trt)-OH, 97%
Sigma-Aldrich
S-Benzyl-L-cysteine, 97%